Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause [Seeking Alpha]
Inventiva S.A. - American Depository Shares (IVA)
Company Research
Source: Seeking Alpha
Publication of results from phase IIa LEGEND study, using lanifibranor in combination with Jardiance for the treatment of patients with NASH and Type 2 Diabetes, expected Q1 of 2024. The global non-alcoholic steatohepatitis treatment market size is expected to reach $48.3 billion by the end of 2035. Several competitors in NASH, but the company might overcome most with the fact that oral administration can be given; Another option to beat the competition would be through combination treatments such as lanifibranor + Jardiance. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Inventiva S.A. NASDAQ: IVA ) recently announced that enrollment had to be paused in the ongoing phase III NATiV3 trial, using its drug lanifibranor for the treatment of patients with non-alcoholic steatohepatitis [NASH]. The reason for the voluntarily pause of this late-stage study was because of one patients with a treatment-related serious adv
Show less
Read more
Impact Snapshot
Event Time:
IVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVA alerts
High impacting Inventiva S.A. - American Depository Shares news events
Weekly update
A roundup of the hottest topics
IVA
News
- Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2024 Featuring 100+ Companies and 110+ Pipeline Drugs Including Lanifibranor (Inventiva Pharma), MSDC-0602K (Cirius Therapeutics), TERN-501 (Terns Pharma) [Yahoo! Finance]Yahoo! Finance
- Inventiva S.A. (NASDAQ: IVA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F [Yahoo! Finance]Yahoo! Finance
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FGlobeNewswire
- Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
IVA
Sec Filings
- 5/3/24 - Form SC
- 4/3/24 - Form 20-F
- 3/27/24 - Form 6-K
- IVA's page on the SEC website